Am-Fam 400

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

FDA’s list of off-patent drugs suggests higher approvals of first generics in 2022

We usher in 2023 with the key highlights of the US Food and Drug Administration’s December 202

Chinese industrial activity revival at 98.6 percent, officials assure of API supplies

While the world feels the heat of the Covid-19 pandemic with the global pharmaceutical supply chain

Pharma Deals, Investments and M&As in January 2018

As we come to an end of the shortest month of the year, we are back this week with another edition o

FDA proposes delayed track and trace rollout; GSK forays into artificial intelligence-aided drug research

This week, Phispers brings you news on an apex court ruling in Canada that overhauls its patent law

Teva CEO steps down; FDA Warning Letters to firms in Japan, India & China

This week, Phispers highlights more bad news for Israeli drugmaker Teva, along with news on the &lsq

Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?

 Over 700 commonly used generic medicines were recommended for suspension by the European Medic